Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR)

NCT04152889 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT04152889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04152889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 Sequenced by Camrelizumab+S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR)
Lead sponsor
RenJi Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
April 14, 2020
Completion date
December 31, 2022
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer stage iii